Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
SAFFRON-301
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT04921358 ↗
- Terminated
- BeiGene
- Focused
We haven't built an HCP commentary report on SAFFRON-301 (sitravatinib plus tislelizumab in locally advanced or metastatic non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SAFFRON-301 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Antibody
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Tislelizumab; Docetaxel; Sitravatinib
- Arms
- Tislelizumab + Sitravatinib · Experimental
- Docetaxel · Active comparator
- Enrollment
- 377
- Primary outcomes
- Overall Survival (OS)
- Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)
- Sponsor
- BeiGene
- Start
- Jul 27, 2021
- Primary completion
- Dec 20, 2023
- Results posted
- Yes
- Registry record
- NCT04921358 · updated Jun 29, 2025
Publications
linked from the registry- Zhou Q, Zhao J, Gao B, et al. SAFFRON-301: A Phase 3 Study of Tislelizumab With Sitravatinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy and an Anti-PD-1/PD-L1 Antibody. Poster presented at: ESMO Congress 2022; September, 2022; Paris, France.
- Zhou Q, Gao B, et al. SAFFRON-301: Sitravatinib PLUS Tislelizumab in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1.
- Zhou Q, Gao B, Hu J, Zhao J, Wang M, He K, Zhang W, Liu C, Fang J, Li XY, Wang Z, Matos M, Kwatra V, Zheng W, Wang C, Chen Y, Zhang J, Wang J, Wu YL. SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. BMJ Oncol. 2026 Feb 19;5(1):e000890. doi: 10.1136/bmjonc-2025-000890. eCollection 2026. PubMed 41737914